Financial statement of Jilin Xidian Pharmaceutical Technology Development Co., Ltd. in 2021
Financial statement report of 2021
Jilin Xidian pharmaceutical science and Technology Development Co., Ltd. (hereinafter referred to as “the company”) has completed the financial settlement in 2021. The financial accounting report is prepared in accordance with the accounting standards for business enterprises. Dahua Certified Public Accountants (special general partnership) has issued a standard audit report with no qualified opinions. Dahua Shen Zi [2022] No. 001402. Now the relevant financial settlement is briefly reported as follows, For details, please refer to the financial report in the company’s annual report. 1、 Financial situation
Unit: Yuan
Increase and decrease range of the project from December 31, 2021 to December 31, 2020
Total assets 594606181265507 Guizhou Sanli Pharmaceutical Co.Ltd(603439) 0 7.96%
Total current assets 3149293567026850313509 17.29%
Total non current assets 2796768245628225720881 -0.91%
Total liabilities 70468124897864137974 – 10.39%
Total current liabilities 34689358143978040027 – 12.80%
Total non current liabilities 35778766753886097947 – 7.93%
Share capital 60602957006060295700 0.00%
Capital reserve 9063976565 0.00%
Surplus reserve 55831031045062912182 10.27%
Undistributed profit 3170643026827024711969 17.32%
Total shareholders’ equity 5241380563747211896416 11.02%
The higher change range of current assets in the current period is mainly due to the larger increase in the ending balance of bank deposits in the current period compared with the previous year and the higher change range of undistributed profits. It is mainly due to the fact that the company paid dividends in 2020 in accordance with the articles of Association and other relevant systems, and the company did not pay dividends in 2021. 2、 Operating results
Unit: Yuan
Increase and decrease of the project in 2021 and 2020
1、 Operating income 2856559321128631871928 – 0.23%
Less: operating cost 46702549924391213122 6.36%
Taxes and surcharges 679118136711794545 – 4.59%
Sales expenses 1529534113916452608508 – 7.03%
Administrative expenses 17228568051802804237 – 4.43%
R & D expenses 1331414604436569124 204.97%
Financial expenses -260436756 -188805525 37.94%
Plus: other income 751632242697672544 7.73%
Investment income (loss expressed with “-“) 120697261196546849 – 38.59%
Financial statement of Jilin Xidian Pharmaceutical Technology Development Co., Ltd. in 2021
Credit impairment loss (loss expressed with “-“) – 223143086679479 – 434.07%
Asset impairment loss (loss expressed with “-“) – 10104346 -377374257754%
Income from asset disposal (loss expressed with “-“) — 1943932 – 100.00%
2、 Operating profit 59669551405924355483 0.72%
Plus: non operating income 400000-——
Less: non operating expenses 4669667031677751 47.41%
3、 Total profit 59206584705892677732 0.47%
Less: income tax expense 718749249918434185 – 21.74%
4、 Net profit 52019092214974243547 4.58%
The higher change range of financial expenses in the current period is mainly due to the increase of the ending balance of bank deposits in the current period compared with the previous year, and the corresponding increase of interest income of financial expenses; The change range of R & D expenses is relatively high, mainly because with the improvement of the epidemic form in 2021, the company can smoothly carry out R & D activities with external R & D institutions. With the continuous development of several projects such as protein iron succinate oral solution and calcium citrate API, the R & D expenses in this period have increased significantly; The higher change range of investment income is mainly due to the decline of overall structural deposit yield, the higher change range of credit impairment loss is mainly due to the provision for bad debts of accounts receivable and other receivables in the current period, the higher change range of asset impairment loss is mainly due to the provision for inventory falling price, and the higher change range of income tax expense is mainly due to the higher R & D expenses in the current period, According to the enterprise income tax law and other relevant laws and regulations, the R & D fee can be deducted more.
3、 Cash flow
Unit: Yuan
Increase and decrease of the project in 2021 and 2020
Net cash flow from operating activities 59013817046454178189 – 8.56%
Net cash flow from investment activities -1806218811 -3051200980 -40.80%
Net cash flow from financing activities -5961475 -2824618280 -99.79%
Ending balance of cash and cash equivalents 1480730909010718107672 38.15%
The net cash flow generated by investment activities has a high range of change, mainly due to the structural deposits purchased in the current period in 2020 and not redeemed at the end of 2020, so the net cash outflow generated by investment activities in 2020 is high; The net cash flow generated from financing activities has a high range of change, mainly because the company paid dividends in 2020 in accordance with the articles of association and other relevant systems, and the company did not pay dividends in 2021.
Board of directors of Jilin Xidian Pharmaceutical Technology Development Co., Ltd
Financial statement of Jilin Xidian Pharmaceutical Technology Development Co., Ltd. in 2021
April 22, 2022
